Glucagen

Glucagen is a prescription injectable medication that contains the peptide hormone glucagon as its active ingredient. It is supplied as an injection solution, typically in a prefilled syringe or vial, with a strength that varies by market but is not specified here. Glucagen is approved in the European Union for emergency treatment of severe hypoglycemia and is administered by intramuscular, intravenous, or subcutaneous routes in clinical practice.

Glucagen is indicated for the rapid reversal of severe hypoglycemia when oral carbohydrate intake is insufficient or impossible.

- Emergency treatment of hypoglycemia in diabetic patients. - Use in unconscious patients with blood glucose < 50 mg/dL. - Administration when glucagon response is needed during insulin overdose. - Treatment of hypoglycemia in children and adults when immediate glucose elevation is required. - Use by healthcare professionals in hospital or pre‑hospital settings. - Administration by trained personnel in emergency kits for rapid self‑treatment when professional help is delayed.

Glucagen may cause a range of adverse effects, most of which are transient and related to its pharmacologic action on blood glucose and the injection site. These effects usually resolve without intervention, but monitoring is recommended after administration, especially immediately.

Common: - Nausea or vomiting. - Flushing or warmth sensation. - Headache. - Injection site pain, redness, or swelling. - Dizziness or light‑headed feeling. - Transient increase in blood pressure. - Mild tremor or shakiness.

Serious: - Severe allergic reaction (anaphylaxis) with rash, itching, swelling of face or throat. - Rapid heart rate (tachycardia) or palpitations. - Hypotension or fainting. - Persistent hyperglycemia requiring medical attention. - Severe abdominal pain. - Persistent vomiting. - Acute pancreatitis (rare).

Glucagen should be used with caution in specific patient populations and clinical situations to minimize risks.

- Verify severe hypoglycemia before administration; do not give if blood glucose is above 70 mg/dL. - Use only when trained personnel are available to manage potential adverse reactions. - Adjust dose in pediatric patients according to weight and clinical guidelines. - Avoid use in patients with known hypersensitivity to glucagon or any formulation components. - Monitor cardiovascular status, especially in patients with heart disease, after injection. - Store the product according to manufacturer instructions to maintain potency. - Discard any solution that appears discolored or contains particles.

Glucagen can interact with other medications or substances that affect glucose metabolism or cardiovascular function.

Avoid: - Concomitant use of beta‑blockers that may mask signs of hypoglycemia. - Simultaneous administration of other glucagon‑like agents without medical supervision. - Use with caution in patients receiving glucagon antagonists, as efficacy may be reduced.

Use with caution: - Insulin analogs or high‑dose insulin therapy, as they may increase the need for repeated glucagon dosing. - Oral hypoglycemic agents, especially sulfonylureas, which can predispose to recurrent hypoglycemia. - Catecholamine‑releasing drugs (e.g., epinephrine) that may augment cardiovascular effects. - Diuretics that may alter electrolyte balance and affect glucagon action.